SC Engineering Launches New Joint Cartilage Regeneration Treatment Product Through Subsidiary

Cellontech, a subsidiary of SC Engineering, is strengthening its lineup of bio-collagen medical device products through the launch of a new product.

Cellontech, a bio company specializing in regenerative medicine, announced on the 17th that it has launched a new product called ‘CartiSeal’ used for joint cartilage regeneration treatment.

CartiSeal is a porous sponge-type ‘implantable tissue regeneration scaffold’ made from bio-collagen (medical collagen registered in the U.S. Food and Drug Administration (FDA) Drug Master File (DMF) and other sources) that promotes the formation of joint cartilage.

CartiSeal is the first domestically produced implantable tissue regeneration scaffold using collagen to be commercialized in Korea. It serves as a scaffold that supports the positioning of cartilage cells and bone marrow cells during procedures such as improved microfracture surgery or autologous bone marrow stem cell therapy, effectively inducing cartilage tissue regeneration.

In particular, CartiSeal was developed using bio-collagen with a sophisticated porous structure, excellent biocompatibility, and superior tissue regeneration capabilities, differentiating it from existing products, according to the company. When implanted in joint cartilage defect areas, CartiSeal facilitates smooth cell infiltration within the tissue and is completely biodegradable in the body, providing an optimal environment for joint cartilage regeneration treatment.

A representative from Cellontech stated, “Since implantable tissue regeneration scaffolds using collagen have so far depended on imports, CartiSeal, which combines technological expertise, product quality, and price competitiveness, can become a promising domestic alternative. We plan to introduce a variety of product lines that can create new revenue sources through our proprietary bio-collagen and cell therapy-based regenerative medical technology know-how.”

Meanwhile, Cellontech received medical device approval from the Ministry of Food and Drug Safety for CartiSeal in August last year. Subsequently, in January of this year, it was registered as a treatment material by the Health Insurance Review and Assessment Service, completing all procedures for market launch and beginning full-scale sales.